AGP Executive Report

Cancer Care: A federally funded study reports that medical marijuana improves cancer-related symptoms and may help reduce opioid use. Cannabinoid Research: A new explainer weighs CBN sleep aid benefits and risks and clarifies how it differs from CBD. Sleep and Anxiety: Recent coverage flags potential downsides: cannabis may worsen sleep quality, and high use may trigger anxiety. Veterinary Guidance: A new Maryland law limits board action against veterinarians who discuss cannabis and CBD. Hemp Innovation: Researchers say hemp hurd fiber could offer a sustainable alternative to peat in container growing.

Community Investment: Vermont cannabis operator Magic Mann says its BTV Local & Indigenous Fund has distributed more than $175,000, including over $75,000 for Indigenous people, culture and communities. Company Watch: Emyria, which began in cannabinoid research, is now expanding its Empax psychedelic-therapy clinics after a sharp rise in annual revenue; funding and execution remain key tests. Hemp Market: Elixinol’s proposed Vitable supplement-platform acquisition would add subscription revenue, with most of the price paid in shares; due diligence and owner approval are still pending. Medicinal Cannabis: Cann Group faces pressure from prescribing curbs, putting its cultivation, manufacturing and Satipharm capsule business under scrutiny as it pursues export growth. Biopharma: Argent BioPharma is sharpening its focus on immune science after globally licensing CannEpil, naming RGT-CA91980 its lead in-house drug program and adding healthy-ageing research.

Community Impact: Vermont cannabis company Magic Mann says its BTV Local & Indigenous Fund has distributed more than $175,000 since its launch, including over $75,000 for Indigenous communities and initiatives. Cultivation: A Minnesota grower is harvesting its first outdoor cannabis crop in Cohasset as it builds an indoor facility; the company says its expansion could bring the workforce to 60–70. Hemp Pharma: South Korea’s North Gyeongsang Province plans a 175 billion won hemp hub in Andong, linking raw-material production with active ingredients and finished medicines by 2030. Market Outlook: Hemp businesses face a looming December deadline that could sharply restrict THC products, while reform advocates are urging Congress to keep them legal. Cannabinoid Research: A University of Regina study is exploring CBD as a concussion treatment, and the FDA has cleared a pathway for conditional approval of a cannabinoid drug for canine bone-cancer pain.

Community Giving: Vermont cannabis company Magic Mann says its BTV Local & Indigenous Fund has distributed more than $175,000 to community causes, including over $75,000 for Indigenous communities and initiatives. CBD Research: The University of Regina is studying CBD as a possible concussion treatment, while the FDA has cleared a pathway for conditional approval of a cannabinoid drug for canine bone-cancer pain. Cannabis Science: New coverage examines how heavy cannabis use may trigger anxiety in the brain and reports that cannabis may undermine sleep quality, even when it makes users drowsy. Medical Programs: New York regulators approved a trial using an oral THC solution for sciatica-related chronic pain. Massachusetts also set aside $1 million for cannabis education, though advocates say the funding falls short.

Retail Expansion: Green Thumb opened RISE Cape Coral, its 25th Florida dispensary and more than 120th nationwide. Hemp Policy: U.S. hemp-THC businesses face a December deadline that could sharply restrict the market; reform advocates are urging Congress to keep these products legal amid uncertainty. CBD Access: A new Maryland law limits veterinary boards’ ability to penalize vets for discussing cannabis and CBD. Research: Recent reports warn that cannabis may worsen sleep quality and that too much may trigger anxiety. Product Development: Avecho is weighing next steps for its CBD sleep capsule, while Elixinol adds a supplement platform. Hemp Innovation: Hemp hurd fiber shows promise as a sustainable alternative to peat in container growing.

Cannabis Research: New reports examine how cannabis may trigger anxiety or paranoia and whether it undermines sleep, despite making users feel drowsy. A separate study asks whether cannabis use is linked to violence, keeping mental-health and safety questions in focus. Hemp Regulation: A marijuana reform group is urging Congress to keep hemp-derived THC products legal, as cultivation rules face fresh scrutiny after a public hearing. CBD Practice: A new Maryland law limits licensing-board action against veterinarians who discuss cannabis and CBD, offering clearer protections for those conversations. Industry & Education: Massachusetts has approved cannabis-education funding, though advocates say the $1 million allocation falls short; meanwhile, hemp hurd is showing promise as a sustainable peat alternative for plant production.

Cannabis Research: A 35-year study linked recent and cumulative cannabis use to poorer objectively measured sleep, though participants didn’t report feeling their sleep was worse. Hemp Policy: A federal delay pushes the scheduled hemp-cannabinoid restrictions to Dec. 11. At the NACS Show, retailers showed growing interest in hemp-derived THC drinks, even as operators warn restrictions threaten the industry. Massachusetts Ballot: Voters will decide Nov. 3 whether to repeal adult-use cannabis sales, potentially upending an $8 billion market while leaving medical sales intact. CBD & Veterinary Care: Maryland’s new law limits board action against veterinarians who discuss cannabis and CBD; the FDA has also cleared a pathway for conditional approval of a cannabinoid drug for canine bone-cancer pain. Community Investment: Vermont’s Magic Mann says its local and Indigenous fund has distributed more than $175,000 to community causes, including over $75,000 for Indigenous communities and initiatives.

Veterinary Policy: A new Maryland law limits veterinary-board action against vets who discuss cannabis and CBD. Separately, the FDA has determined a cannabinoid treatment for canine bone-cancer pain qualifies for a conditional-approval pathway; it is not yet an approved drug. Clinical Research: New York regulators approved a medical-cannabis trial testing an oral THC solution for sciatica-related chronic pain. Federal Rules: Hemp-derived THC businesses face a pivotal deadline: most new federal limits are delayed until Dec. 11, while restrictions on certain cannabinoids not naturally produced by cannabis begin Nov. 12. Hemp Innovation: Hemp hurd is showing promise as a peat alternative for container-grown plants, adding a potential market for hemp materials beyond cannabinoid products.

Industry Results: Tilray Brands reported record first-quarter fiscal 2027 revenue and gross profit, with year-over-year growth across international cannabis, beverages and pharmaceutical distribution. Federal Policy: State officials are pressing the DEA for cannabis-rescheduling guidance as a December deadline threatens to sharply restrict the hemp-derived THC market, valued at $28 billion. Medical Research: New York regulators approved a trial of oral THC for sciatica-related pain; the University of Regina is studying CBD for concussion, and the FDA opened a conditional-approval pathway for a cannabinoid drug for canine bone-cancer pain. Product Safety: A survey found cannabis consumers said QR-coded products made them feel better protected by regulators. Cannabis Science: New research explores why cannabis can trigger paranoia and anxiety, including the brain cells involved. Hemp Innovation: An Australian couple’s hemp-built home highlights the material’s insulation and fire-resistant properties.

Consumer Safeguards: A study found all surveyed cannabis consumers felt state-issued QR codes made them more protected, while nearly 90% said the codes would make them more likely to buy from licensed dispensaries. Pain Research: New York regulators approved a placebo-controlled trial of an oral THC solution for chronic sciatica-related pain, including checks on lasting benefits and safety. CBD Science: University of Regina researchers are studying whether cannabinoids can help manage pain after sports-related concussions, exploring an alternative to opioid treatment. Veterinary Medicine: The FDA has outlined a conditional approval pathway for a cannabinoid drug targeting pain from canine bone cancer; the companies plan to discuss study and manufacturing requirements with the agency in November. Hemp Policy: A looming December deadline could sharply restrict the hemp-derived THC market, adding pressure on businesses as regulators and lawmakers debate product rules.

Federal Hemp Rules: Congress has voted to sharply restrict THC in hemp products starting Dec. 11, putting a market worth more than $30 billion and about 300,000 jobs at risk. Industry advocates are pushing for nationwide rules, including age limits and THC caps, rather than a sweeping crackdown. State Policy: The Texas Hemp Business Council has published a voter guide comparing candidates’ positions on hemp regulation, retail standards and consumer safeguards. Product Standards: An analysis of nearly 145,000 cannabis samples found flower below the established water-activity range in all 10 states studied, renewing calls for consistent standards to protect quality and safety. CBD Coverage: A marijuana-opponents group and a pharmaceutical company have asked a court to block a federal plan for Medicare coverage of hemp-derived CBD. Hemp Processing: Montana’s IND Hemp has opened a fiber-processing line to produce ready-to-spin U.S.-grown hemp for manufacturers.

Cannabis Enforcement: Gardaí in Cork arrested two men in their 20s after a raid in Togher turned up suspected cannabis worth about €350,000, with samples headed to Forensic Science Ireland. Cambodia Policy: Prime Minister Hun Manet reiterated Cambodia will not allow cannabis cultivation, saying it can’t be effectively controlled, and also rejected investment in e-cigarette and vape production amid youth public-health concerns. Clinical CBD/Regulatory Path: Avecho (ASX:AVE) says its Phase III insomnia trial cleared an interim analysis and it plans to engage the US FDA and Europe’s EMA, aiming to finish the trial by year-end next year and pursue overseas licensing. Corporate Moves in Hemp/Wellness: Elixinol (ASX:EXL) agreed to acquire supplement platform Vitable in an all-scrip, mostly deferred/performance-based deal as it refocuses on Australia. M&A in Medical Cannabis: Curaleaf filed an updated circular to reflect an increased offer to acquire Aurora Cannabis, with implied consideration of US$5.00 per Aurora share. Cannabis Tech & Access: Colorado’s Drop delivery platform is pitching itself as a “DoorDash” for cannabis delivery, aiming to connect licensed dispensaries, transporters, and consumers. Science & Safety: Northwestern researchers identified brain neurons linked to anxiety from cannabinoid exposure in stressful conditions, pointing to somatostatin neurons in the central amygdala.

Hemp & CBD Policy: Rhode Island’s regulated hemp THC drinks market is bracing for a federal clampdown—starting Dec. 11, products over 0.4 mg total THC per container could be forced off shelves, threatening growers and retailers. Retail & Licensing: Minnesota’s Tree Huggers Cannabis marked its Caledonia “re-grand opening,” shifting from a lower-potency hemp edible shop to a full adult-use dispensary with flower, vapes, edibles, CBD products, and more. Industry & M&A: Capsoil Technologies acquired Red Mesa Science & Refining to scale Liposoll, its liposomal delivery tech used across nutraceuticals, cosmetics, and cannabinoid-focused formulas. Business & Compliance: Safe Harbor reported rising client deposits for the regulated cannabis and hemp sector, signaling continued demand for banking and lending services. Research & Health: A large review in Psychological Medicine links cannabis use with higher odds of violence, including stronger associations tied to criminal convictions. Community & Education: MADD Canada and Manitoba Public Insurance launched a school tour warning that alcohol and cannabis are involved in more than half of youth crashes. Tech & Operations: Adaptive Information Systems outlined an integrated managed IT and cybersecurity model for Monterey Bay businesses, including cannabis operators.

Medical Cannabis Market Moves: SOMAÍ launched its in-house medical flower brand Soma OG in Switzerland via Dascoli Pharma, debuting cultivars Soap Mints, The Big Apple, and Cake & Chem. Post-Harvest Tech + Veterans: Cannatrol teamed with Operation Green Healing as the exclusive nonprofit partner for its Cool Cure Limited Edition program, funding veterans’ wellness through sales. Hemp Feed Safety Research: New work on hemp processing residue explores how cannabinoid traces may transfer into animal products, with regulators and producers focused on migration risk and clearance after feeding stops. Regulatory/Compliance Updates: Manitoba proposed easing rules so cannabis stores can remove window coverings that block public view, citing staff safety concerns after a Winnipeg assault. Consumer Protection Push: San Diego launched a Consumer Fairness and Public Protection Unit and sued AppLovin over alleged bypassing of parental controls on kids’ devices, with additional suits targeting Roblox and Polymaker. Local Policy + Tax Funding: Colorado Springs’ 2027 budget proposal leans on marijuana tax revenue for police tech and fire equipment, alongside restoring services after prior shortfalls. Agritech Investment: Grand Farm won a $5M federal award to expand its Indoor AgTech Test Track for year-round equipment and autonomy testing.

Hemp THC Policy Fight: A multibillion-dollar hemp THC market is bracing for a looming federal ban after Congress moved to close a loophole, pushing the effective date from Nov. 12 to Dec. 11—giving lawmakers more time to decide whether to regulate instead of eliminate. M&A Watch: Curaleaf sweetened its hostile bid for Edmonton’s Aurora Cannabis to $5 per Aurora share (up from $4), signaling a push to win over shareholders and accelerate a merger. Medical Cannabis Research: FDA is seeking public input on early-stage clinical trial design for ibogaine, aiming to balance potential therapies with serious safety concerns. Science & Safety: Northwestern researchers identified brain neurons tied to anxiety after cannabinoid exposure in mice, offering a possible explanation for “good trip” turning bad under stress. Veterans & Wellness: Cannatrol’s Cool Cure Limited Edition program added Operation Green Healing as its exclusive veterans nonprofit partner, funding outreach via sales. Public Health/Compliance: A new VA records-based op-ed argues rising cannabis use disorder diagnoses among veterans may be shaped by changing diagnostic rules, not just behavior. Regulatory/Enforcement: Police in Estonia say QR stickers near schools are steering users to online drug shops, raising fears about access by minors.

Medical Cannabis R&D: Avecho Biotechnology (ASX:AVE) is pushing ahead with recruitment for the second cohort of its pivotal CBD insomnia capsule trial after an independent data monitoring board backed full enrollment, with no serious adverse events reported at interim review. Telehealth & Distribution: Vitura Health (ASX:VIT) is resetting after a setback tied to Bupa Australia redirecting international members away from its Doctors on Demand service, adding pressure amid scrutiny of closed-loop prescribing and supply models. Regulatory/Enforcement: Hong Kong Customs seized about 6kg of suspected cannabis buds at the airport (about $1.2M value) and arrested a passenger; investigations continue. Industry/Operations: Cannatrol says Operation Green Healing has joined its Cool Cure Limited Edition program as the exclusive nonprofit partner for veterans and military families, funded via a share of sales. Policy & Workplace: A 2026 Quest Diagnostics index finds more workers test positive for marijuana, while some employers are easing pre-employment screening—raising potential workers’ comp and liability risks. Global Biosecurity: China’s Ministry of State Security warns of genetic resource theft and cross-border biosecurity risks tied to blood samples, exotic pets, and plant seeds.